Literature DB >> 33015789

Clinical significance of circ-MTHFD2 in diagnosis, pathological staging and prognosis of NSCLC.

Q-Q Geng1, Q-F Wu, Y Zhang, G-J Zhang, J-K Fu, N-Z Chen.   

Abstract

OBJECTIVE: To explore the clinical significance of circ-MTHFD2 in the diagnosis, pathological staging, and prognosis of non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: A total of 100 pairs of cancer tissues and adjacent tissues were surgically removed from NSCLC patients treated from July 2011 to January 2013 in our hospital were selected. All tissue samples were pathologically confirmed. Real Time-Polymerase Chain Reaction (qRT-PCR) was adopted to detect the expression of circ-MTHFD2 in NSCLC samples and its characteristic as a circular ribonucleic acid (circRNA). The receiver operating characteristic (ROC) curve was drawn to determine the diagnostic potential of circ-MTHFD2 in NSCLC. The relationship between circ-MTHFD2 expression and the clinical characteristics of NSCLC patients was analyzed by the χ2-test. Kaplan-Meier survival curves were depicted to assess the prognostic potential of circ-MTHFD2 in NSCLC. The effect of circ-MTHFD2 on the overall survival rate of NSCLC patients was uncovered by introducing the Cox proportional hazards model.
RESULTS: The expression of circ-MTHFD2 in cancer tissues of NSCLC patients was higher than that in adjacent tissues (p<0.05), and there was no remarkable difference in the expression of circ-MTHFD2 before and after RNase R digestion (p>0.05). The area under the curve (AUC) of circ-MTHFD2 ROC was 0.701, with the cut-off value of 3.534, 90% sensitivity and 71% specificity. Circ-MTHFD2 expression was closely associated with smoking history, tumor size, tumor-node-metastasis (TNM) stage, lymph node metastasis, and recurrence in NSCLC patients (p<0.05). The prognosis of NSCLC patients with high expression of circ-MTHFD2 was evidently poorer than those with low expression. High expression of circ-MTHFD2 was an independent risk factor affecting the prognosis in NSCLC (p<0.05).
CONCLUSIONS: The high expression of circ-MTHFD2 has clinical significance in the diagnosis, pathological staging, and prognosis of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33015789     DOI: 10.26355/eurrev_202009_23032

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Circ_CSPP1 Regulates the Development of Non-small Cell Lung Cancer via the miR-486-3p/BRD9 Axis.

Authors:  Dan Xie; Shuyi Zhang; Xiaocong Jiang; Weizhen Huang; Ying He; Yi Li; Sihan Chen; Hailin Xiong
Journal:  Biochem Genet       Date:  2022-06-09       Impact factor: 1.890

2.  Immune Characteristics Analysis and Transcriptional Regulation Prediction Based on Gene Signatures of Chronic Obstructive Pulmonary Disease.

Authors:  Hui Yu; Weikang Guo; Yunduo Liu; Yaoxian Wang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-11-05

3.  Circular RNA Eps15-homology domain containing protein 2 motivates proliferation, glycolysis but refrains autophagy in non-small cell lung cancer via crosstalk with microRNA-3186-3p and forkhead box K1.

Authors:  Fan Zhang; Tieying Zhang; ZiRan Zhao; Ying Ji; Yue Peng; Liang Zhao
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 4.  Role of circular RNAs in the diagnosis, regulation of drug resistance and prognosis of lung cancer.

Authors:  Chengpeng Sang; Dingyu Rao; Caixia Wu; Yao Xia; Maoyan Si; Zhixian Tang
Journal:  Oncol Lett       Date:  2022-07-07       Impact factor: 3.111

5.  ATF4/MYC Regulates MTHFD2 to Promote NSCLC Progression by Mediating Redox Homeostasis.

Authors:  Yixing Gao; Lan Feng; Luping Zhang; Jianhui Geng; Erlong Zhang
Journal:  Dis Markers       Date:  2022-08-22       Impact factor: 3.464

Review 6.  Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives.

Authors:  Huan-Huan Chen; Tie-Ning Zhang; Qi-Jun Wu; Xin-Mei Huang; Yu-Hong Zhao
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.